SLC6A16

Across TCGA pan-cancer cohorts, SLC6A16 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SLC6A16 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher SLC6A16 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC6A16 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

ESCA, BRCA, and THCA are the cancer types where SLC6A16 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.108	0.703	<.001	36	view →
BRCA	OS	Median	III,IV	0.191	0.833	<.001	22	view →
THCA	OS	Median	All	0.186	0.952	<.001	12	view →
LUSC	OS	Median	III,IV	0.262	0.676	.003	12	view →
UCEC	OS	Median	All	1.000	0.660	.027	10	view →
PRAD	DFS	Median	All	0.617	0.886	.011	6	view →
SKCM	DFS	Median	II,III,IV	0.903	0.667	.026	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SLC6A16–ESCA (OS)

Open the ESCA breakdown →